← All trials
NCT06062888
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2024
- Primary completion
- Mar 31, 2027
- Completion date
- Sep 30, 2027
- First posted
- Oct 2, 2023
- Last posted
- Oct 2, 2023
- Enrollment
- 264
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Northwestern UniversityLead sponsor
- Medical College of WisconsinCollaborator
- Northwestern UniversityOverall official - principal investigator
- Northwestern UniversityReponsible party - principal investigator
- Oregon Health and Science UniversityCollaborator
- University of Southern CaliforniaCollaborator
- University of California, DavisCollaborator
- Vanderbilt UniversityCollaborator
- University of Alabama, BirminghamCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.